|
|
News Breaks | | | | February 28, 2013 | | 09:28 EDT |  | RPRX | Repros granted end of Phase 2 meeting in late May for Proellex-V by FDA
Repros Therapeutics announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application. Once the meeting is held, the company will report the outcome to the financial community in a timely fashion. | |
|
News For RPRX From The Last 14 Days Check below for free stories on RPRX the last two weeks. |
|
|
| May 10, 2013 | | 09:26 EDT |  | RPRX | Repros Therapeutics reports Q1 EPS (41c), consensus (35c)
 Subscribe for More Information | |
|
|
|
|
|
|
